¿Cómo paga?
¿Qué concentración? Elija la suya
¿Cuántas tabletas?

Cómo pagar lo menos posible

Sin seguro

$6,880+ por 30 tabletas

Las farmacias pagan aproximadamente esto por Rinvoq; usted pagaría más.

Qué hacer

  1. Pregunte en su farmacia el precio sin seguro de Rinvoq, y también en una o dos farmacias más.

Otras opciones

Gratis del fabricante, si cumple los requisitos myAbbVie Assist. Our income guidelines are based on the size of your household and annual income. O llame al 1-800-222-6885.

Ver si cumple los requisitos 

Todavía no se vende ningún genérico.

Compare todas las opciones

De marca

Rinvoq, el original

Al menos$6,880por 30 tabletas; las farmacias pagan esto
Formas de ahorrar en Rinvoq

La tarjeta del fabricante

RINVOQ Complete Savings Card

Tarjeta de ahorro de AbbVie

El fabricante de Rinvoq tiene un programa de ahorro. Revise su página para ver las condiciones de hoy.

Inscríbase en rinvoq.com 

O llame al 1-800-274-6867. Vea la oferta en rinvoq.com

Del sitio web del fabricante, revisado el 2 de noviembre de 2026. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.

Genérico autorizado

No existe ninguno.

No se vendeNo existe ninguno

Genérico regular

Todavía no se vende ningún genérico.

No se vendeNinguno a la venta aún

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor.

  • RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
  • RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
  • RINVOQ is indicated for the treatment of adults with giant cell arteritis Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

Fuente: la etiqueta de la FDA de Rinvoq (AbbVie Inc.), 30 de junio de 2026. Etiqueta completa en DailyMed 

Datos útiles

  • “Seguro comercial” quiere decir un plan de su trabajo, del Mercado de Seguros Médicos o uno que usted compra por su cuenta. Un plan para jubilados que forma parte de Medicare cuenta como Medicare. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.
  • La mayoría de las tarjetas requieren inscribirse en el sitio web del fabricante, y muchas solo funcionan si su plan cubre el medicamento. Después, dé los datos de la tarjeta a su farmacia.
  • No deje ni cambie un medicamento sin hablar con su farmacéutico o su médico.